Drug Trial Radar · NCT07253142
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 5, 2026
Primary completion
Jun 18, 2027
Study completion Jun 19, 2028
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.
Conditions
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
Interventions
HLX43 dose 1Drug
HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
HLX43 dose 2Drug
HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to 24 week
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
THE Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Fujian Cancer Hospital
Fu'zhou, Fujian, China
Cancer Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The People's Hospital of Guangxi Zhuangzu Autonomous Region
Nanning, Guangxi, China
Cangzhou People's Hospital
Cangzhou, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Hubei Cancer Hospital
Wuha, Hubei, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.